T1	Participants 106 150	advanced non-small-cell lung cancer (NSCLC):
T2	Participants 551 676	Since July 1996, 198 patients with non-operable NSCLC and measurable disease without previous chemotherapy entered the trial.
T3	Participants 677 707	Ninety nine patients (group A)
